With growing demand for eye drugs in Asia, Novartis' Alcon unit wants to have the capacity to sell into that market. To be able to do that, the company has opened a new plant in Singapore to make a variety of its eye drugs.
Parexel is stretching its global network of clinical trial supply operations with a new distribution center in Singapore, bringing the facility online to better support studies across the globe.
As drugmakers expand drug development and manufacturing around the world, logistics become important and often challenging. Suppliers, as well as drugmakers, have to figure out how to get ingredients and supplies to new destinations. Parexel is latching onto that opportunity with a new distribution center in Singapore, as well as expansion of operations in Billerica, MA.
Novartis is expanding a plant in Singapore and the international engineering and construction firm PM Group is helping.
Humira, the best-selling drug in the world, continues to power the top and bottom lines for the year-old pharma spinoff AbbVie. But the drugmaker has a pipeline of new products it is looking to get approved, and for that it says it needs some more production capacity.
Singapore has become a biopharma manufacturing hub, drawing the likes of Novartis, GlaxoSmithKline and Amgen. Even Russia's Pharmstandard has an API facility there. Now AbbVie will join the group.
Bayer has again reached out to DKSH to expand its presence in Asia, this time tasking the Swiss company with helping it push its therapies in Singapore.
Medtronic is setting up a de facto incubator in Singapore, planning to design, test and scale new business models for the developing world.
It apparently was not enough that the owner of a company that makes the active pharmaceutical ingredients for a couple of Pharmstandard's key OTC products is a member of its board; Pharmstandard said today it will pay him nearly $600 million for his company to secure a long-term supply of the ingredients.
Despite slumping royalty revenue, Singapore's Biosensors is counting on new products and recent acquisitions to carry it to 15% growth in fiscal 2014, expecting more than $386 million for the year.